Latissimus Dorsi Activity During Different Exercises (L-DORSI-EMG)

December 22, 2025 updated by: Irem Duzgun, Hacettepe University

Investigation of Latissimus Dorsi Muscle Activation During Different Exercises

This single-visit, laboratory study will quantify latissimus dorsi activation during standardized band/body-weight exercises commonly used in rehabilitation (e.g., standing bent-over row, inferior glide, seated press-up, body-lifting). Healthy, physically active adults (18-40 y; Tegner ≥5) will perform three repetitions per exercise with metronome-paced phases (≈3 s concentric, 3 s isometric, 3 s eccentric), 5-s rest between repetitions and 2-min between exercises; load will be individualized to reach OMNI RPE 6-8. Surface EMG (TeleMyo DTS; Noraxon) will be recorded from the latissimus dorsi (medial and lateral) and selected synergists (teres major, infraspinatus, posterior deltoid, triceps); electrode placement will follow SENIAM recommendations. Signals will be band-pass filtered (20-500 Hz), rectified, RMS-smoothed with a 100-ms window, and normalized to %MVIC using standardized MVC tests; exercise/MVC order will be randomized to limit bias. The primary outcome is mean normalized EMG amplitude per exercise; secondary outcomes include peak amplitude and categorical activation levels (low ≤20% MVIC, moderate 21-40%, high 41-60%, very high >60%). The study involves minimal risk (possible mild skin irritation under electrodes and transient post-exercise fatigue).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The latissimus dorsi (LD) originates from the spinous processes of the lower six thoracic vertebrae and the thoracolumbar fascia/iliac crest, and-together with the teres major-attaches to the medial lip of the intertubercular groove of the humerus. Functionally, LD contributes to shoulder adduction, internal rotation, and extension, linking the upper limb to the trunk. Alongside the rotator cuff, prevention of superior translation of the humeral head may be provided by the glenohumeral adductors (pectoralis major and LD) acting as humeral head depressors via a medio-inferior vector created by their tendon orientation. From an osteokinematic perspective, LD may protect against subacromial pain by facilitating inferior glide of the humeral head on the glenoid.

Selecting an appropriate strengthening exercise is critical to restore muscle performance and functional arm elevation in patients with shoulder injury or dysfunction. The literature emphasizes exercises targeting activation of the rotator cuff and scapulothoracic muscles that contribute to functional elevation. Surface electromyography (sEMG) is commonly used to guide exercise selection and progression by quantifying a muscle's contribution across different exercises, thereby enabling evidence-based advancement in strengthening programs.

However, much of the existing LD literature centers on lateral pull-down variations, with limited data for rehabilitation-relevant tasks such as low row, inferior glide, bent-over row (with trunk flexion), seated press-up, and body-lifting. Focusing on a single exercise limits clinical decision-making for shoulder rehabilitation (exercise selection and progression). Therefore, to support a scientific, evidence-based progression for LD strengthening in rehabilitation, this study was planned to obtain comprehensive sEMG data across multiple exercises.

Aim: To examine LD EMG activation levels during different exercises and determine between-exercise differences.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Altındag
      • Ankara, Altındag, Turkey (Türkiye), 06100
        • Recruiting
        • Hacettepe University
        • Contact:
        • Sub-Investigator:
          • Gizem Soylu, MSc
        • Sub-Investigator:
          • Kubra Caylan Gurses, MSc
        • Sub-Investigator:
          • Ceyda Sevinc, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Healthy, physically active adults aged 18-40 years. Eligibility requires Tegner ≥5, full glenohumeral range of motion, no shoulder/cervical/lumbar complaints in the past 6 months, and no systemic or neurological disease.

Description

Inclusion Criteria:

  • Age 18-40 years
  • No range-of-motion restriction at the glenohumeral joint
  • No shoulder, cervical, or lumbar region complaints/injury within the past 6 months
  • No systemic or neurological disease
  • Competent to consent and provides written informed consent
  • Tegner Activity Scale ≥ 5

Exclusion Criteria:

  • Body mass index (BMI) > 25 kg/m²

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy adults
Single-visit laboratory cohort. Physically active adults perform exercises; surface EMG is recorded from the latissimus dorsi
Participants will perform six standardized pulling tasks-inferior glide, low row, seated row, bent-over row, seated press-up, and body lifting-using a resistance band or body weight. Each exercise is done for 3 repetitions with ~5 s between reps and ~2 min between exercises. Resisted exercises follow a metronome-paced 3 s concentric / 3 s isometric / 3 s eccentric tempo; purely isometric tasks are held for 3 s. Load is individualized with the OMNI 0-10 scale and increased during up to 10 familiarization reps until perceived exertion reaches 6-8/10. Exercise order is randomized to minimize ordering effects.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Electromyography
Time Frame: Baseline (Day 1)
Surface EMG from the latissimus dorsi (medial and lateral sites) will be recorded with an 8-channel system (TeleMyo DTS; Noraxon). Skin will be shaved and cleaned with 70% isopropyl alcohol; bipolar Ag/AgCl electrodes will be placed per SENIAM with a 2 cm inter-electrode distance (MLD ~lateral to T9; LLD ~4 cm inferior to the scapular inferior angle, midway between the spine and lateral trunk). A synchronized video (Logitech C920) will mark movement onset/offset and will be deleted after analysis (no copies kept). Signals will be normalized to %MVIC using three 5-s MVIC trials (30-s rest between trials; ~2-min between muscles) performed in standardized positions with verbal encouragement. The outcome is the mean %MVIC during the steady phase of each exercise.
Baseline (Day 1)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Electromyography-Other muscles
Time Frame: Baseline (Day 1)
Surface EMG will also be recorded from teres major, infraspinatus, posterior deltoid, and triceps using the same preparation, SENIAM-based placement, and processing/normalization procedures described above. The outcome is the mean normalized EMG amplitude (%MVIC) during the steady phase of each exercise (isometric: central 3-s window; resisted: concentric 3 sec -isometric 3 sec- eccentric 3 sec).
Baseline (Day 1)
Activity Level
Time Frame: Baseline (Day 1)
Baseline physical activity will be characterized using the Tegner Activity Scale (0-10) prior to testing; higher scores indicate greater habitual activity.
Baseline (Day 1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 12, 2025

Primary Completion (Estimated)

February 25, 2026

Study Completion (Estimated)

February 25, 2026

Study Registration Dates

First Submitted

December 9, 2025

First Submitted That Met QC Criteria

December 9, 2025

First Posted (Estimated)

December 22, 2025

Study Record Updates

Last Update Posted (Actual)

December 29, 2025

Last Update Submitted That Met QC Criteria

December 22, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No individual participant data (IPD) will be shared. De-identified aggregate results will be disseminated in publications. The dataset includes physiological signals; synchronized videos are deleted after analysis.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Activation

Clinical Trials on Exercise

Subscribe